Evidence map›Paper›PMID 39820832›Full record

ArticleAAPS PharmSciTech2025

A New and Safe Delivery of Sildenafil Citrate Co-Evaporate Loaded Emulgels for the Cure of Certain Male Sexual Dysfunctions.

Shaaban K Osman, Abobakr M Yassin, Taher M Yassin, Ahmed M Mohammed, Ahmed M Abdelsalam, Wael A Mahdi, Sultan Alshehri, Mohamed A El Hamd, Ahmed A H Abdellatif, Mohammed A Amin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shaaban K OsmanDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt. shaabanosman@azhar.edu.eg.
Abobakr M YassinDepartment of Pharmacy Investigator, Pharmacy Department, Sohag, Egypt.
Taher M YassinDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Minofia University, Minofia, Egypt.
Ahmed M MohammedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt.
Ahmed M AbdelsalamDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt.
Wael A MahdiDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
Sultan AlshehriDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
Mohamed A El HamdDepartment of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, 11961, Shaqra, Saudi Arabia. aboelhamdmohamed@su.edu.sa.ORCID http://orcid.org/0000-0002-9774-0587
Ahmed A H AbdellatifDepartment of Pharmaceutics, College of Pharmacy, Qassim University, 51452, Qassim, Saudi Arabia. a.abdellatif@qu.edu.sa.ORCID http://orcid.org/0000-0002-3186-1896
Mohammed A AminDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt.
Emad A TahaDepartment of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present work focuses on the production of sildenafil co-evaporates loaded emulgels as topical dosage forms for the treatment of premature ejaculation and erectile dysfunction. Topical administration of sildenafil citrate (SILD) co-evaporates is expected to improve the bioavailability profile of the drug and to avoid the severe side effects accompanying the traditional SILD dosage forms, especially for prohibited cardiovascular cases. Firstly, the solubility of SILD was improved via solid dispersion via co-evaporation technique using PEG-5KDa and PVP-K90 as hydrophilic carriers. The modified co-evaporates were characterized by DSC, XRD, and solubility studies. Different emulgels, loaded with SILD co-evaporates, were formulated and characterized by different analyses including the viscosity, stability, spreadability, and in vitro release studies. Finally, the clinical activity of the chosen formula was accomplished via the application of the emulgels on volunteers suffering from erectile dysfunction. The results showed that the prepared SILD/PVP K90 of 1:2 w/w ratio exhibited the highest solubility and dissolution rate. All formulated emulgels exhibited good physicochemical properties. Especially, the emulgel formula composed of 2%w/v HPMC, loaded with SILD /PVP- K90, revealed the highest release rate. The release mechanism of SILD from emulgels fits with the Korsmeyer Peppas mechanism. The results of in vivo studies indicated a significant improvement of both IVLT and IIEF-5 parameters in mild to moderate ED, accompanied by PE. The modified SILD emulgel is an alternative promising and safe transdermal drug delivery system for the management and treatment of mild to moderate ED with PE.

Indexed as

Erectile DysfunctionSildenafil CitrateVasodilator AgentsAdministration, TopicalDrug CarriersDrug CompoundingGelsHumansMaleSolubilityX-Ray DiffractionDrug CarriersGelsSildenafil CitrateVasodilator Agentsemulgelserectile dysfunctionin vitro studymajor clinical studypremature ejaculationsildenafilsolid dispersion

Identifiers

PMID39820832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.